Selective reduction of striatal type II glucocorticoid receptors in rats by 3,4-methylenedioxymethamphetamine (MDMA)

Martin T. Lowy; J. Frank Nash; Herbert Y. Meltzer

doi:10.1016/0014-2999(89)90411-1

Selective reduction of striatal type II glucocorticoid receptors in rats by 3,4-methylenedioxymethamphetamine (MDMA)

Martin T. Lowy^*, J. Frank Nash, Herbert Y. Meltzer

^*Corresponding author for this work

Psychiatry and Behavioral Sciences

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Abstract

A single 20 mg/kg dose of 3,4-methylenedioxymethamphetamine (MDMA) administered to rats markedly decreased serotonin (5-HT) and 5-hydroxyindoleacetic acid (5-HIAA) levels in hippocampus, frontal cortex and striatum seven days following injection. MDMA also significantly decreased type II glucocorticoid receptor levels in the striatum, but not in hippocampus or frontal cortex. Since no difference in basal serum corticosterone levels was observed between the two groups, MDMA may decrease striatal type II glucocorticoid receptors via a corticosterone- independent mechanism.

Original language	English (US)
Pages (from-to)	157-161
Number of pages	5
Journal	European Journal of Pharmacology
Volume	163
Issue number	1
DOIs	https://doi.org/10.1016/0014-2999(89)90411-1
State	Published - Apr 12 1989

Keywords

3,4-Methylenedioxymethamphetamine (MDMA)
5-Hydroxytryptamine
Corticosterone
Glucocorticoid receptors
Neurotoxicity
Striatum

ASJC Scopus subject areas

Pharmacology

Access to Document

10.1016/0014-2999(89)90411-1

Cite this

@article{88e55252f8f04ef894fe8121abbaed68,

title = "Selective reduction of striatal type II glucocorticoid receptors in rats by 3,4-methylenedioxymethamphetamine (MDMA)",

abstract = "A single 20 mg/kg dose of 3,4-methylenedioxymethamphetamine (MDMA) administered to rats markedly decreased serotonin (5-HT) and 5-hydroxyindoleacetic acid (5-HIAA) levels in hippocampus, frontal cortex and striatum seven days following injection. MDMA also significantly decreased type II glucocorticoid receptor levels in the striatum, but not in hippocampus or frontal cortex. Since no difference in basal serum corticosterone levels was observed between the two groups, MDMA may decrease striatal type II glucocorticoid receptors via a corticosterone- independent mechanism.",

keywords = "3,4-Methylenedioxymethamphetamine (MDMA), 5-Hydroxytryptamine, Corticosterone, Glucocorticoid receptors, Neurotoxicity, Striatum",

author = "Lowy, {Martin T.} and {Frank Nash}, J. and Meltzer, {Herbert Y.}",

note = "Funding Information: The research reported was supported in part by USPHS Grants BRSG RR-05410-26 (M.T.L.), RO3 MH 44339 (M.T.L.) and MH 41684 (H.Y.M.). J.F.N. is the recipient of a NARSAD Fellowship extension award. H.Y.M. is the recipient of a USPHS Research Career Scientist Award MH 47808. We are grateful to Ms. Lee Mason for her secretarial assistance in preparing this manuscript.",

year = "1989",

month = apr,

day = "12",

doi = "10.1016/0014-2999(89)90411-1",

language = "English (US)",

volume = "163",

pages = "157--161",

journal = "European Journal of Pharmacology",

issn = "0014-2999",

publisher = "Elsevier",

number = "1",

}

TY - JOUR

T1 - Selective reduction of striatal type II glucocorticoid receptors in rats by 3,4-methylenedioxymethamphetamine (MDMA)

AU - Lowy, Martin T.

AU - Frank Nash, J.

AU - Meltzer, Herbert Y.

N1 - Funding Information: The research reported was supported in part by USPHS Grants BRSG RR-05410-26 (M.T.L.), RO3 MH 44339 (M.T.L.) and MH 41684 (H.Y.M.). J.F.N. is the recipient of a NARSAD Fellowship extension award. H.Y.M. is the recipient of a USPHS Research Career Scientist Award MH 47808. We are grateful to Ms. Lee Mason for her secretarial assistance in preparing this manuscript.

PY - 1989/4/12

Y1 - 1989/4/12

N2 - A single 20 mg/kg dose of 3,4-methylenedioxymethamphetamine (MDMA) administered to rats markedly decreased serotonin (5-HT) and 5-hydroxyindoleacetic acid (5-HIAA) levels in hippocampus, frontal cortex and striatum seven days following injection. MDMA also significantly decreased type II glucocorticoid receptor levels in the striatum, but not in hippocampus or frontal cortex. Since no difference in basal serum corticosterone levels was observed between the two groups, MDMA may decrease striatal type II glucocorticoid receptors via a corticosterone- independent mechanism.

AB - A single 20 mg/kg dose of 3,4-methylenedioxymethamphetamine (MDMA) administered to rats markedly decreased serotonin (5-HT) and 5-hydroxyindoleacetic acid (5-HIAA) levels in hippocampus, frontal cortex and striatum seven days following injection. MDMA also significantly decreased type II glucocorticoid receptor levels in the striatum, but not in hippocampus or frontal cortex. Since no difference in basal serum corticosterone levels was observed between the two groups, MDMA may decrease striatal type II glucocorticoid receptors via a corticosterone- independent mechanism.

KW - 3,4-Methylenedioxymethamphetamine (MDMA)

KW - 5-Hydroxytryptamine

KW - Corticosterone

KW - Glucocorticoid receptors

KW - Neurotoxicity

KW - Striatum

UR - http://www.scopus.com/inward/record.url?scp=0024542085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024542085&partnerID=8YFLogxK

U2 - 10.1016/0014-2999(89)90411-1

DO - 10.1016/0014-2999(89)90411-1

M3 - Article

C2 - 2472965

AN - SCOPUS:0024542085

VL - 163

SP - 157

EP - 161

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1

ER -

Selective reduction of striatal type II glucocorticoid receptors in rats by 3,4-methylenedioxymethamphetamine (MDMA)

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this